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Abstract
The detection of circulating galactomannan (GM) in serum samples is an important step in the diagnosis of invasive aspergillosis (IA).
The assay has been mainly explored in neutropenic patients, and is now used to monitor patients at high risk for IA. However, the per-
formance of the assay varies greatly among studies. The objective of this study was to explore the impact of the neutrophil count on
the GM serum index at the time of IA diagnosis. Ninety-nine episodes of proven or probable, microbiologically documented IA in 91
patients with haematological malignancies were studied retrospectively. Three groups were identiﬁed: groups 1–3, with <100 polymor-
phonuclear neutrophils (PMN)/mm3 (n = 18), between 100 and 500 PMN/mm3 (n = 21), or >500 PMN/mm3 (n = 60), respectively. The
mean GM index was signiﬁcantly higher in group 1 than in the other groups (p <0.05). This ﬁnding did not change after stratifying the
analysis with regard to the use of antibiotics likely to give false-positive GM results or with regard to treatment effective against fungi
before the diagnosis of IA. This ﬁnding could be considered in the routine use of the GM antigenaemia test in non-neutropenic patients;
a negative result or a low GM index should not eliminate the diagnosis of IA. This limitation calls for other microbiological tests, includ-
ing analysis of bronchoalveolar lavage ﬂuid, to establish a deﬁnitive diagnosis of IA.
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Invasive aspergillosis (IA) is the most frequent and one of
the most lethal invasive fungal infections in high-risk haema-
tology patients, especially in stem cell transplant (SCT) reci-
pients [1]. The diagnosis of IA is difﬁcult and relies in part
on the detection of galactomannan (GM), which can be done
using a sandwich ELISA (GM EIA) that is commercially avail-
able (Platelia Aspergillus, Biorad, France). GM is a misused
term that refers to a family of molecules harbouring galacto-
furanose antigens [2]. These molecules are released by grow-
ing hyphae and during mycelial breakdown. Wide ranges of
sensitivities and speciﬁcities have been reported in the litera-
ture concerning GM EIA for the early diagnosis of IA [2].
The larger series of Maertens et al., which was autopsy-
controlled, showed a sensitivity of 92.6%, a speciﬁcity of
95.4%, and positive and negative predictive values of 93% and
95%, respectively, supporting the routine use of the test for
screening neutropenic patients at risk of IA [3]. Because the
early initiation of antifungal treatment may improve the prog-
nosis of IA, GM EIA has been established as a useful tool for
the early diagnosis of IA in neutropenic patients [4,5].
Numerous questions have arisen, however, about the sen-
sitivity and speciﬁcity of GM EIA. A recent meta-analysis
reports a pooled sensitivity of 64% and a pooled speciﬁcity of
93%, with great differences among centres and studies [6].
The sensitivity and speciﬁcity were especially low in solid
organ transplant patients. Among the factors that may explain
these differences is the intensity of neutropenia, which has
not been explored in previous studies. Most of the studies of
GM have involved severely neutropenic patients, screened
two or three times weekly during a neutropenic risk period.
Less attention has been paid to the diagnostic yield of the test
in assessing non-neutropenic patients, who currently com-
prise the main proportion of the population of haematology
patients with IA, especially allogeneic SCT recipients [1].
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Indeed, neutropenia is not the only risk factor for IA, and
many patients receiving immunosuppressive drugs, mainly
high-dose steroids, are at risk of developing IA while they
are not neutropenic [1,7]. The aim of the study was to
determine whether the diagnostic yield of GM EIA was com-




The haematology department of Hoˆpital Henri Mondor, Paris
comprises 40 beds in four units, two with laminar airﬂow
rooms, with 12 or six beds, one unit with eight private
rooms, and one unit with seven double rooms (14 beds).
Routinely, patients under treatment for acute leukaemia or
receiving myelo-ablative SCT are given non-absorbable oral
antibacterials and polyens for gut decontamination. No anti-
bacterial or antifungal prophylaxis is undertaken for the
other patients, with the exception of oral penicillin for
patients having had a previous splenectomy. Patients with
pneumonia are usually examined using ﬁbreoptic broncho-
scopy, bronchoalveolar lavage (BAL), and/or protected
aspiration. No systematic computed tomography scan
screening is performed routinely, independent of the neutro-
phil count.
The episodes of IA occurring in the haematology depart-
ment are prospectively classiﬁed according to the EORTC-
MSG criteria as proven, probable or possible [8]. From 1
January 2000 to 31 December 2005, 126 episodes of proven
or probable IA were observed in the department. For the
purpose of the study, 17 episodes were rejected from the
cohort because the diagnosis was based only on GM results
with clinical or imaging signs, but without direct or culture
documentation of Aspergillus. Among the 17 episodes, there
was one for which no neutrophil count was available within
48 h of IA diagnosis, and there were ten episodes for which
no GM test was undertaken within 5 days before or after
isolation of the fungus. Consequently, all of the IA episodes
selected for the analysis were microbiologically documented,
by direct microscopic examination for aspergillus hyphae, by
culture, or by both. For all episodes, there was a corre-
sponding GM EIA result and a neutrophil count within 48 h
before or after the day of diagnosis of IA.
Episode classiﬁcation
According to the neutrophil counts within 48 h of IA
diagnosis, the episodes were assigned to group 1 (<100 poly-
morphonuclear neutrophils (PMN)/mm3; n = 18), group 2
(100–500 PMN/mm3; n = 21), or group 3 (>500 PMN/mm3;
n = 60). Patients were considered to have received steroids
if their daily dose was ‡10 mg of prednisone or equivalent.
All the data concerning antibiotics administered at the
time of serum sampling for the GM assay were collected.
Among these antibiotics, those considered likely to provoke
false-positive GM EIA results were piperacillin (including
piperacillin–tazobactam) and amoxycillin (including amoxycil-
lin–clavulanate) [9,10]. Data concerning any systemic treat-
ment effective against fungi (intravenous amphotericin B
deoxycholate or liposomal formulation, voriconazole, itraco-
nazole and caspofungin) were also collected at the time of
GM EIA, independently of whether the treatment was
empirical or not.
No antifungal prophylaxis was given during the studied
period. Patients with a diagnosis of IA were treated differ-
ently according to the date of diagnosis. Most patients were
given voriconazole as ﬁrst-line therapy as soon as the drug
was available in France (mid-2002). Before this time, they
received conventional amphotericin B, a liposomal formula-
tion of amphotericin B, or itraconazole.
GM testing
All neutropenic patients who were expected to be neutrope-
nic for at least 10 days, especially SCT recipients, and acute
leukaemia and aplastic anaemia patients, were routinely
screened twice weekly for serum GM. GM EIA screening
was undertaken once weekly for all allogeneic SCT recipients
after recovery from neutropenia until at least day 100, or
later in cases of graft-versus-host disease that required
further immunosuppressive treatment. GM EIA was also
undertaken in a case-by-case approach to document episodes
of pneumonia, in conjunction with ﬁbroscopy and BAL. BAL
ﬂuids were not routinely tested for the presence of GM.
Serum samples were processed under a laminar ﬂow cabi-
net and kept at 4C for less than 2 days until GM EIA was
performed according to the manufacturer’s recommenda-
tions. Each run included a negative control (Tris buffer saline
alone), two positive controls containing 1 lg GM/L, used to
calculate the GM index (optical density (OD) of sample/mean
OD of the two 1 lg/L controls), and one control containing
5.6 lg/L. The value considered for each case was the highest
patient GM index within ±5 days of the microbiological doc-
umentation of IA.
Statistical analysis
The characteristics of the three groups were compared by
using Fisher’s exact test for qualitative variables and the non-
parametric Kruskall–Wallis test for quantitative variables.
The GM indices were also compared among groups by using
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Dunn’s multiple comparisons test, after stratiﬁcation by ster-
oid or antibiotic use. Quantitative variables were reported as
median (range). Categorical variables were reported as num-
ber (percentages). Data were analysed using Stata statistical
software (Release 8.0; StataCorp 2003, College Station, TX,
USA). A p-value <0.05 was considered to be signiﬁcant.
Results
Ninety-nine episodes of proven (n = 8) or probable (n = 91)
IA were studied in 91 patients (60 males, 31 females). The
clinical characteristics of the patients are shown in Table 1.
In 96 (97%) episodes, there was lung involvement. The cases
were microbiologically documented by positive microscopy
alone (n = 6), positive culture (n = 65), or both (n = 28).
The GM indices were signiﬁcantly different among the
three groups (Table 1). When groups were compared by
pairs, the GM index was signiﬁcantly higher in group 1 than
in group 2 and group 3. The proportions of patients with a
GM index above the cut-offs of 1, 0.7 and 0.5 were also sig-
niﬁcantly higher in group 1 than in group 2 and group 3.
There was no signiﬁcant difference between group 2 and
group 3.
The GM index of group 1 (<100 PMN) was signiﬁcantly
higher than that of the two other groups together, as the
proportions of patients with a GM index higher than or
equal to 1, 0.7, and 0.5 (Table 2).
The proportions of patients receiving antibiotics that were
possibly responsible for false-positive GM results were not
statistically different among groups. When the analysis was
stratiﬁed according to the fact that patients did not receive
TABLE 1. Clinical characteristics, galactomannan (GM) antigenaemia indices and treatments at the time of the GM result in
the 99 episodes of proven or probable invasive aspergillosis (IA) as related to the three groups deﬁned according to the
polymorphonuclear neutrophil (PMN) counts
Group 1 (n = 18) Group 2 (n = 21) Group 3 (n = 60)
Total (n = 99)<100 PMN 100–500 PMN >500 PMN
Sex ratio, M/F 10/8 13/8 44/16 67/32
Age, years, median (range) 54.6 (20–72) 65.6 (33–85) 57.6 (15–80) 58.0 (15–85)
Underlying diseases, no.
Acute myeloid leukaemia 10 6 16 32
Acute lymphoblastic leukaemia 2 0 3 5
Lymphoma 3 5 18 26
Chronic myeloid leukaemia 0 0 4 4
Chronic lymphoid leukaemia 2 10 12 24
Other 1 0 7 8
Stem cell transplant, no.
Allogeneic 1 0 24 25
Autologous 1 0 6 7
Aspergillus infection, no.
Proven 4 2 2 8
Probable 14 19 58 91
Aspergillus spp., no.
A. fumigatus 12 18 45 75
A. ﬂavus 4 2 3 9
A. niger 0 1 3 4
Others 0 0 2 2
Undetermined 0 0 3 3
Site involved, no.
Lung 17 21 53 91
Sinus 1 0 1 2
Lung and sinus 0 0 5 5
Other 0 0 1 1
Steroids ‡10 mga, no. (%) 4 (22.2) 3 (14.3) 26 (43.3) 33 (33.3)
Antibiotics as potential source of false GM
positivityb, no. (%)
5 (27.8) 7 (33.3) 22 (36.7) 34 (34.3)
Systemic antifungal drugsc, no. (%) 5 (27.8) 5 (23.8) 12 (20.0) 22 (22.2)
Survival at 12 weeks after IA diagnosis, no. (%) 12 (66.7) 15 (71.4) 51 (85.0) 78 (78.79)
GM index, median (range)d 0.61 (0.08–5.84) 0.16 (0.08–2.91) 0.2 (0.04–5.31) 0.205 (0.04–5.84)
No. (%) of IA cases with a GM index ‡1e 8 (44.4) 3 (14.3) 5 (8.3) 16 (16.2)
No. (%) of IA cases with a GM index ‡0.7f 8 (44.4) 3 (14.3) 9 (15.0) 20 (20.2)
No. (%) of IA cases with a GM index ‡0.5g 11 (61.1) 4 (19.0) 11 (18.3) 26 (26.3)
aFisher’s exact test, p 0.03.
bPiperacillin, piperacillin–tazobactam, amoxycillin, and amoxycillin–clavulanate; Fisher’s exact test, p 0.8.
cIntravenous amphotericin B deoxycholate or liposomal formulation, itraconazole; Fisher’s exact test, p 0.7.
dKruskall–Wallis test, p 0.04. Dunn’s multiple comparisons test: group 1 vs. group 2, p <0.05; group 1 vs. group 3, p <0.01; group 2 vs. group 3, p >0.05.
eFisher’s exact test, p 0.002.
fFisher’s exact test, p 0.03.
gFisher’s exact test, p 0.002.
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these antibiotics at the time of IA diagnosis, the GM index
remained higher in group 1 than in the combined groups 2
and 3 (Table 2). When the analysis was stratiﬁed according
to treatment with antifungal therapy at the time of IA diag-
nosis, the GM index of patients receiving antifungal therapy
was not statistically different between group 1 and the com-
bined groups 2 and 3 (Table 2). However, the GM index
was higher in group 1 when the patients did not receive anti-
fungal therapy. For the analysis after stratiﬁcation according
to steroid use, the GM index of patients receiving steroids
was signiﬁcantly higher in group 1 than in the combined
groups 2 and 3 (Table 2).
Discussion
In a cohort of 91 haematology patients with 99 episodes of
proven or probable IA, microbiologically documented by
either direct microscopic examination or culture of Aspergil-
lus sp., the GM index was signiﬁcantly higher in severely neu-
tropenic patients (<100 PMN/mm3) than in the other
patients. This was true independently of the administration
of antibiotics likely to give false-positive results in the GM
test, a matter of concern for clinicians routinely using the
test [9–15]. The classiﬁcation of patients according to differ-
ent GM ratio cut-offs, as proposed by some authors [16–
18], rather than according to the OD sample/OD control
ratio, does not change the results. Therefore, the diagnostic
yield of the GM EIA could differ according to the absence or
presence of neutropenia. As GM EIA is widely used for pro-
spective screening of patients at risk for IA in Europe, this
ﬁnding is important in light of the observation of more and
more cases of IA in the non-neutropenic phases of haemato-
logical diseases.
Very few data are available in the literature, speciﬁcally data
concerning non-neutropenic patients or concerning the rela-
tionship between GM titres and neutrophil count at the time
of diagnosis of IA, even from very large series [3,5]. This is
probably due to the low number of non-neutropenic patients
in most series. Prospective studies have focused on the inves-
tigation of neutropenic patients, considered to be the popula-
tion more at risk of IA among haematology patients. Among
13 allogeneic SCT recipients with proven IA, none of the
three non-neutropenic patients had positive results according
to GM EIA, whereas eight of ten neutropenic patients had
positive results at a 0.5 cut-off [18]. Two other reports have
presented negative GM EIA results in patients with chronic
granulomatous diseases [19] or Job’s syndrome (Walsh et al.,
Reduced expression of galactomannan antigenemia in patients
with invasive aspergillosis and chronic granulomatous disease
or Job’s syndrome. Proceedings of the 40th Annual Meeting
of the Infectious Diseases Society of America, Chicago, Sep-
tember 2002) for whom neutropenia is not the main risk fac-
tor for IA. Similarly, a recent meta-analysis of the
performance of GM EIA for proven and probable IA showed
that the population with lower sensitivity and speciﬁcity is the
population of solid organ transplant recipients, who are
usually not neutropenic [6]. Additionally, in a study of 26
immunocompromised patients on mechanical ventilation with
proven IA, it was suggested that determination of GM levels
in serum was signiﬁcantly more reliable in patients with neu-
tropenia, whereas the test performed equally well when BAL
ﬂuid of neutropenic (n = 10) and non-neutropenic (n = 16)
patients was analysed [20].
The ﬁndings of the current study clearly show, in a larger
cohort of patients, that neutropenia can affect the diagnostic
yield of the test. Most of the patients in this study developed
IA after the neutropenic period. In comparison with previous
studies and observations, the number of patients with IA
without neutropenia has increased during the last 10–
15 years [1,7]. Indeed, severely neutropenic patients account
for only 18.2% in the present study, and 60.1% of the
patients had normal white blood counts at the time of diag-
nosis of IA. The small sample size in the groups with
<500 PMN/mm3 might interfere with the statistical analysis.
Hence, the results should be conﬁrmed, or invalidated, by
other clinicians analysing similar populations.
Several hypotheses may be proposed to explain the bet-
ter yield of GM EIA in neutropenic than in non-neutropenic
TABLE 2. Comparison of galactomannan (GM) indices in
group 1 (<100 polymorphonuclear neutrophils (PMN)/mm3)
vs. groups 2 + 3 (‡100 PMN/mm3) when stratifying by
steroids, potentially GM-contaminated antibiotic use, and




Groups 2 + 3
(n = 81)
p<100 PMN ‡100 PMN
GM index ‡1 8 (44.4) 8 (9.9) 0.001a
GM index ‡0.7 8 (44.4) 12 (14.8) 0.009a
GM index ‡0.5 11 (61.1) 15 (18.52) 0.001a
GM index, median (range) 0.61 (0.08–5.84) 0.19 (0.04–5.31) 0.01b
Steroid administration
Yes 4.63 (4.37–5.84) 0.2 (0.04–1.93) 0.001b
No 0.44 (0.08–2.48) 0.18 (0.04–5.31) 0.19b
Potentially GM-contaminated antibiotic(s) use
Yes 4.36 (0.11–5.84) 0.24 (0.04–5.31) 0.76b
No 0.57 (0.08–4.96) 0.18 (0.04–2.01) 0.003b
Antifungal therapy
Yes 0.54 (0.08–2.48) 0.17 (0.1–2.29) 0.694b
No 1.21 (0.1–5.84) 0.20 (0.04–5.31) 0.006b
ap-value of Fischer’s exact test.
bp-value of the non-parametric Kruskall–Wallis test.
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patients. First, the fungal burden at the time of initial IA
diagnosis could be higher in neutropenic patients than in
non-neutropenic patients. The GM titres have been shown
to be quantitatively related to the fungal burden in animal
models [18,21,22]. Recently, in a model of lung Aspergillus
infection in mice, GM concentrations were very low in ster-
oid-treated mice as compared to those observed in mice
that had undergone chemotherapy [21], suggesting that fun-
gal development was more extensive and systemic in the
latter. Similarly, steroid therapy was observed more fre-
quently in the non-neutropenic group, which had the lower
mean GM index. A large autopsy series in patients with
haematological malignancies showed different histopathologi-
cal patterns in neutropenic patients when compared to SCT
recipients with graft-versus-host disease; neutropenic
patients had a high Aspergillus burden, more angio-invasion
and less inﬂammation as compared to non-neutropenic SCT
recipients [23]. Moreover, the fungal load is deemed to be
greater in patients with a poor outcome; hence the higher
GM titre values in these patients [24,25]. As the survival at
3 months after diagnosis was better, although not signiﬁcant
statistically, in the non-neutropenic groups of the current
study, this may be an additional indirect argument in favour
of this ﬁrst hypothesis.
On the other hand, antifungal therapy can interfere with
GM EIA performance in decreasing the fungal burden, and
therefore the GM index [18]. Indeed, patients with
< 100 PMN/mL who were not receiving antifungal therapy
had a higher GM index than those receiving this therapy
(Table 2). The risk of a poor performance of GM EIA in
patients under prophylaxis with drugs effective against fungi
such as posaconazole [26,27] should be kept in mind.
Another likely hypothesis could be that the IA lesions are
less limited in neutropenic patients, due to the lack of neu-
trophils and to the deﬁcient inﬂammatory process [23]. This
may create favourable conditions for the GM to be more
easily released into the circulation, whereas its natural pro-
duction by growing hyphae in non-neutropenic patients is
probably limited to the infected area by an inﬂammatory pro-
cess tending to decrease the risk of dissemination. The
macrophage deﬁciency that is often associated with pro-
longed chemotherapy-induced neutropenia [28] could also
impact on GM clearance from the bloodstream by macro-
phage mannosyl receptors [29]. Another related explanation
might be the presence of antibodies complexing the GM and,
as a consequence, lowering the titres in non-neutropenic
patients who are able to mount an antibody response against
GM [16]. However, as the ELISA procedure includes heating
of the serum in the presence of EDTA to dissociate com-
plexes and to precipitate serum proteins that may interfere
with the immunoenzymatic reaction, this latter explanation
seems unlikely.
According to a third hypothesis, the level of certainty of
the IA diagnosis based on ﬁbreoptic bronchoscopy and BAL
analysis might not be the same in neutropenic and non-neu-
tropenic patients. In other words, some of the non-neutro-
penic patients might be colonized rather than deeply infected
when a BAL analysis reveals an Aspergillus sp. in the lung sam-
ples, whereas this ﬁnding could have more diagnostic value
in neutropenic patients. Diagnosis no longer relies on autop-
sies at Hoˆpital Henri Mondor, Paris, and biopsy specimens
are difﬁcult to obtain in the thrombocytopenic patients. The
usual means of investigating pneumonia is the analysis of BAL
ﬂuids or other respiratory specimens. As a consequence,
diagnostic tools are optimally evaluated by investigating prob-
able cases [8].
On the other hand, it is impossible to include a group
without IA as a comparator, as it is extremely difﬁcult to
exclude IA in high-risk haematology patients without an
autopsy. As a result, the microbiological criteria might be dif-
ferently weighted according to the host factors, steroids ver-
sus deep neutropenia.
Other factors, e.g. radiologically detectable alterations, fre-
quency of blood sampling, or the time interval between ﬁrst
symptoms and diagnosis, could inﬂuence the GM index.
However, owing to the small numbers of patients in the neu-
tropenic patient groups, and the retrospective design of the
study, the factors to be studied were not augmented. A pro-
spective study would be more appropriate for that purpose.
In cases of microbiologically documented probable or pro-
ven IA in haematology patients, the GM index is higher in
severely neutropenic patients (<100 PMN) than in other
(‡100 PMN) patients. Whatever the reasons for the lower
diagnostic yield of GM EIA in non-neutropenic patients, this
could explain previous discrepancies among studies concern-
ing the clinical relevance of GM assay, in which the patients
were not stratiﬁed according to neutrophil counts. This
observation should be kept in mind in the routine use of
GM assay in non-neutropenic patients; a negative result
should not eliminate the diagnosis of IA, and should encou-
rage other investigations, mainly BAL analysis, to establish or
eliminate the diagnosis of IA.
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